Praxis Precision Medicines PRAX
Praxis Precision Medicines reported a net loss of $94.23 million for the three months ended Sep 30, 2026.
Praxis Precision Medicines (PRAX) filed a 10-Q with the SEC on Nov 9, 2026, 4:32 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001689548-26-000089
- Net loss: $94.23 million for the three months ended Sep 30, 2026
- Diluted EPS: -$3.23 for the three months ended Sep 30, 2026
- Cash and equivalents: $361.85 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
